Seer says European Patent Office upholds key particle-based proteomics patent
PUBT · 3d ago
Share
Listen to the news
- Seer reported the European Patent Office will maintain EP4056263, covering particle-based protein enrichment for proteomics; a written decision is expected in about two months.
- The patent is owned by Brigham and Women’s Hospital, which exclusively licenses it to Seer.
- The U.S. International Trade Commission opened an investigation into Nanomics imports tied to alleged infringement of five Seer U.S. patents.
- Seer is seeking a limited exclusion order targeting Nanomics Proteonano kits and workstations; Brigham and Women’s Hospital joined as co-complainant.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seer Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607010700PRIMZONEFULLFEED9755430) on July 01, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved